Nektar Therapeutics (NKTR) Discusses Topline Results From REZOLVE-AA Phase 2b Study of rezpegaldesleukin in Alopecia Areata Transcript
Summarize this article with:
SA Transcripts157.38K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Nektar Therapeutics (NKTR) Discusses Topline Results From REZOLVE-AA Phase 2b Study of rezpegaldesleukin in Alopecia Areata December 16, 2025 8:00 AM EST Company Participants Vivian Wu - Investor RelationsHoward W. Robin - CEO, President & DirectorJonathan Zalevsky - Senior VP and Chief Research & Development OfficerMary Tagliaferri - Chief Medical Officer Conference Call Participants Jonathan SilverbergBenjamin UngarDavid RosmarinYasmeen Rahimi - Piper Sandler & Co., Research DivisionJulian Harrison - BTIG, LLC, Research DivisionJay Olson - Oppenheimer & Co. Inc., Research DivisionJiale Song - Jefferies LLC, Research DivisionYu He - H.C. Wainwright & Co, LLC, Research DivisionSamantha Semenkow - Citigroup Inc., Research DivisionMayank Mamtani - B. Riley Securities, Inc., Research DivisionTsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Presentation Operator Ladies and gentlemen, thank you for joining us, and welcome to Nektar Therapeutics' Analyst and Investor event to discuss RESOLVE-AA top line results. [Operator Instructions] I will now hand the conference over to Vivian Wu, Investor Relations and Corporate Affairs. Vivian, please go ahead. Vivian WuInvestor Relations Thank you, and good morning, everyone. Thank you for joining us today. Today, you will hear from Howard Robin, our President and Chief Executive Officer; Dr. Jonathan Zalevsky, our Chief Research and Development Officer; and Dr. Mary Tagliaferri, our Chief Medical Officer. Our KOL panel and renowned experts in dermatology and alopecia areata, Dr. Jonathan Silverberg, Dr. David Rosmarin and Dr. Benjamin Ungar will also be available during the Q&A portion. On today's call, we expect to make forward-looking statements regarding our business, including statements regarding the therapy potential of and future development plans for rezpegaldesleukin, the timing and plans for future clinical data presentations and other statements regarding the future of our business. Because forward-looking statements relate to the future, they are subject to uncertainties and risks that are difficult to predict, many of which